Posted by Michael Wonder on 05 Apr 2023
Verismo Therapeutics secures fast track designation from the US FDA for SynKIR-110
5 April 2023 - SynKIR-110 addresses gaps in treatment options for those with malignant pleural mesothelioma, a rare and aggressive cancer that affects the lining of the chest or abdominal cavities.
Verismo Therapeutics today announced that it has received fast track designation from the US FDA for its investigational new drug, SynKIR-110, for the treatment of patients with mesothelioma.
